NCT06007391View on ClinicalTrials.gov

Tolerance and Efficacy Nicotinamide (vitamin B3) in Dominant Optic Atrophy OPA1

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions

Nicotinamide Adverse Reaction

Interventions

DRUG

Nicotinamide

nicotinamide 3g per day

Trial Locations (1)

Unknown

RECRUITING

Angers University Hospital, Angers

All Listed Sponsors

lead

University Hospital, Angers

OTHER_GOV